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Key factors which concur to the
correct therapeutic evaluation of
herbal products in free
radical-induced diseases
Cesare Mancuso*
Institute of Pharmacology, Catholic University School of Medicine, Roma, Italy
For many years now the world’s scientific literature has been perfused with articles on
the therapeutic potential of natural products, the vast majority of which have herbal
origins, as in the case of free radical-induced diseases. What is often overlooked is the
effort of researchers who take into consideration the preclinical and clinical evaluation
of these herbal products, in order to demonstrate the therapeutic efficacy and safety.
The first critical issue to be addressed in the early stages of the preclinical studies is
related to pharmacokinetics, which is sometimes not very favorable, of some of these
products, which limits the bioavailability after oral intake. In this regard, it is worthy
underlining how it is often unethical to propose the therapeutic efficacy of a compound
on the basis of preclinical results obtained with far higher concentrations to those which,
hopefully, could be achieved in organs and tissues of subjects taking these products
by mouth. The most widely used approach to overcome the problem related to the
low bioavailability involves the complexation of the active ingredients of herbal products
with non-toxic carriers that facilitate the absorption and distribution. Even the induction
or inhibition of drug metabolizing enzymes by herbal products, and the consequent
variations of plasma concentrations of co-administered drugs, are phenomena to be
carefully evaluated as they can give rise to side-effects. This risk is even greater when
considering that people lack the perception of the risk arising from an over use of herbal
products that, by their very nature, are considered risk-free.
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Introduction
For many years the use of natural products derived from herbs (thereafter “herbal products”), has
been proposed as adjuvant therapy in diseases in which free radicals play a key role on the patho-
genesis, e.g., neurodegenerative diseases, cancer, diabetes mellitus, and cardiovascular diseases (Qi
et al., 2010; Mancuso et al., 2012a; Ergin et al., 2013). The reason for scientists’ interest in herbal
products is linked to the fact that a number of preclinical studies have demonstrated the antioxi-
dant and cytoprotective activity of these compounds (Brambilla et al., 2008; Calabrese et al., 2010;
Mancuso et al., 2012a; Mancuso and Santangelo, 2014). Indeed, the data on some relevant clinical
studies summarized in recent reviews and meta-analyzes have argued, partially or in some cases
totally, the evidence obtained from studies of cellular systems or in laboratory animals on alleged
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therapeutic activity of herbal products. The aim of this arti-
cle is not to provide an analytical review of the role played by
herbal products as adjuvants in the treatment of the aforemen-
tioned pathologies (the interested reader may ﬁnd numerous
overviews that extensively examine the biological actions of any
product), yet to analyze critically the main factors that should
be taken into account when deciding on the therapeutic poten-
tial of a product derived from herbs, from the preclinical studies
in animal models to clinical results. Each of these factors will
be discussed considering, for example, some of the herbal prod-
ucts that yield suﬃcient preclinical and clinical pharmacology
data.
As herbal products taken with food or contained in supple-
ments are diﬀerent from “prescription drugs” derived from plants
(e.g., atropine, digitalis, morphine), they are often referred to as
dietary supplements. In light of this, for the purpose of this paper,
the terms “herbal products” and “dietary supplement” will be
considered equivalent.
Pharmacokinetic Factors
Absorption and Distribution
Because of their chemical structure, several herbal products
possess a low solubility and stability in water solution or
are quickly deteriorated in body ﬂuids whose pH is neu-
tral. (–)-Epigallocatechin gallate (EGCG, Figure 1), a polyphe-
nol belonging to the subgroup of ﬂavanols and particu-
larly abundant in green tea, has a stability in water solu-
tion and at the body temperature of 37◦C concentration-
dependent which gradually decreases with the decrease in the
concentration of ECGC and with the contact of the pH of
the solution to 7.4 (Proniuk et al., 2002). For these rea-
sons, under physiological conditions, and to the concentra-
tions that are likely to occur in the blood and tissues, the
amounts of ECGC are neglectable. Similarly, the polyphe-
nols curcumin (CUR, contained in the rhizome of Curcuma
longa Linn., Figure 2) and quercetin (QCT, abundant in
capers, berries, apples, onions, and other leafy green vegeta-
bles, Figure 3), in view of their high hydrophobicity, they have
FIGURE 1 | Chemical structure of (–)-epigallocatechin gallate (EGCG).
FIGURE 2 | Chemical structure of curcumin.
FIGURE 3 | Chemical structure of quercetin (QCT).
a water solubility of about to 1 μg/ml and 2 mg/ml, respec-
tively (Srinivas et al., 2010; Zhang et al., 2011). Due to these
physical–chemical characteristics, EGCG, CUR, and QCT are
poorly absorbed after ingestion and have a very low bioavail-
ability (Wang et al., 2014). This limitation in the absorption has
complicated the ability of clinical trials to evaluate the eﬃcacy
of these natural compounds in numerous diseases, thereby pre-
venting the accumulation of evidence about their utility or not
for man. An eﬀective strategy to increase the bioavailability of
dietary supplements consists in their complexation with various
types of nanoparticles or polysaccharides, e.g., chitosan and tri-
methyl-chitosan (Wang et al., 2014). This technology has been
recently applied to ECGC, CUR, and QCT which were produced
in new formulations that have made a signiﬁcant improvement
in bioavailability; Table 1 shows the variation of the main phar-
macokinetic parameters of EGCG, CUR, and QCT complexed
with diﬀerent types of nanoparticles or polysaccharides. A care-
ful analysis of Table 1 shows the complexation of CUR and QCT
with the diﬀerent types of carriers increases markedly both the
maximum peak concentration (Cmax) and the necessary time
to reach it (Tmax), which suggests a slower, yet more eﬀective
absorption of the active ingredient. Simultaneously, the increase
in the area under the curve (AUC) demonstrates how the pres-
ence of nanoparticles or particles derived from chitosan is capable
of improving the bioavailability and this is particularly evident
in the case of CUR and QCT. The increase in half-life (T1/2) in
the case of formulations based on lipid carriers and polysaccha-
rides implies an extension of the time of persistence of the active
ingredient in the body and, therefore, a more prolonged phar-
macological action. It is worthy emphasizing that the solid–lipid
nanoparticles (SLN) have proved particularly eﬀective carriers
both for the CUR that QCT, thus increasing the bioavailabil-
ity of many degrees of magnitude. As regards the EGCC, the
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TABLE 1 | Summary about the complexation-induced modifications on the main pharmacokinetic parameters of some active ingredients of herbal
products.
Compound/formulation AUC Cmax Tmax T1/2 Reference
ECGC ∼116 nM·ha ∼34.3 nMa 1.5 ha 3.4 ha Dube et al. (2011)
Chitosan-NP-ECGC ∼179 nM·ha ∼37.8 nMa 1.5 ha Dube et al. (2011)
Curcumin (CUR) ∼312 ng/ml·hb ∼245 nMb 0.5 hb ∼1.0 hb Shaikh et al. (2009)
Curcumin-PLGA ∼3224 ng/ml·hc ∼710 nMc 2.0 hc Shaikh et al. (2009)
Curcumin-TMC ∼12760 ng/ml·hd ∼3.3 μMd 2.0 hd ∼12 hd Ramalingam and Ko (2014)
Curcumin-SLN ∼42000 ng/ml·he ∼38 μMe 0.5 he Kakkar et al. (2010)
Quercetin (QCT) ∼56 μg/ml·hf ∼6 μg/mlf 5 hf 6 hf Li et al. (2009)
Quercetin-SLN ∼324 μg/ml·hf ∼12 μg/mlf 8 hf 18 hf Li et al. (2009)
aMale Swiss outbred mice treated with a single oral dose of EGCG or Chitosan-NP-ECGC at the dose of 0.76 mg/kg.
bMale Sprague–Dawley rats treated with 250 mg/kg curcumin per os.
cMale Sprague–Dawley rats treated with 100 mg/kg curcumin-PLGA per os.
dBalb/c mice treated with 50 mg/kg curcumin-TMC per os.
eMale Wistar rats treated with 50 mg/kg curcumin-SLN per os.
fMale Wistar rats treated orally with quercetin or quercetin-SLN suspensions at the dose of 50 mg/kg.
AUC, are under the curve; Cmax, peak plasma concentration; NP, nanoparticles; PLGA, poly(lactic-co-glycolic acid); SLN, solid lipid nanoparticles; Tmax, time to reach the
Cmax; T1/2, half-life; TMC, N-trimethyl Chitosan.
formulation with the derivatives of the chitosan has proved able
to increase the AUC by over 50% compared to an increase inCmax
by only 10%.
One aspect still to be evaluated when using lipid carriers or
polysaccharides is the ability that they are able to “guide” the com-
pound towards the target organs where the accumulation must
occur and this is all the more complex as the organs are protected
by speciﬁc anatomical structures. An example may be the cen-
tral nervous system as the brain and spinal cord are protected by
the blood–brain barrier (BBB), which reduces the penetration of
many substances. In this case, the use of certain formulations has
proven particularly eﬀective. As demonstrated by Ramalingam
and Ko (2014), chitosan is a useful vector for ensuring the accu-
mulation of CUR in the cytosol and in the brain membranes of
rat tissue which increases the chances of a possible use of this
formulation in neurodegenerative diseases. Moreover, the formu-
lation based on SLN, administered orally, or intravenously, allows
a certain accumulation of CUR in the mouse brain (Kakkar et al.,
2010).
A further issue to be considered when deciding to evaluate
a preparation of nanoparticles, particularly when administered
for prolonged periods, is the possible toxicity of the carriers
with which the active ingredients are complexed. The use of
nanoparticles produced using indigestible oils (e.g., mineral oils)
rather than digestible ones (e.g., corn oil) should be avoided
because those produced using the indigestible oils may have
a considerable growth in size due to the aggregation in the
passage from the mouth to the stomach and to the intestine
and this may cause a degree of toxicity for those who take it
(McClements, 2013; Rao et al., 2013). Furthermore, it is always
advisable to avoid the use of vectors in the preparation of which
synthetic surfactants have been used (e.g., sorbitan esters and
their ethoxylates) or organic solvents (e.g., acetone, hexane)
although, currently, there are no reliable data about the quan-
tity of these substances in the ﬁnal product compared to those
used initially for the preparation and, therefore, it is not possi-
ble to determine whether they are comprised within the range of
toxicity. This consideration is particularly true for organic sol-
vents which are also used, for example, in moderate amounts
during the preparation of nanoparticles, but which are subse-
quently evaporated and only traces of which may remain in
the ﬁnished product (McClements, 2013). Moreover, the diam-
eter of the nanoparticles is a factor that could determine side
eﬀects. There is an inverse relationship between the diameter
of the nanoparticles and extent of absorption as the smaller
their diameter (usually between 100 and 1000 nm), the greater
the possibility that they are absorbed by increasing the intra-
cellular concentration of the active ingredient they contain.
Thus, it is worthy considering that, in case of nanoparticles
with a very small diameter, for example, very useful to facili-
tate the passage through the BBB, oral administration can result
in a signiﬁcant absorption at the oral, esophageal, or gastric
level, reducing the amount of active ingredient that reaches
the small intestine which is the site where absorption occurs.
This could lead to the onset of the local, rather than systemic
eﬀects (McClements, 2013). In the case of nanoparticles admin-
istered by IV (e.g., liposomes), whose primary use is a carrier
of antineoplastic drugs and does not seem relevant in the case
of herbal products, it is worthy considering the risk of non-
allergic hypersensitivity reactions due to complement activation
(Wacker, 2013).
The inﬂuence of the processes of absorption and distribution
in determining the bioavailability and blood and tissue concen-
trations of a dietary supplement, points out, if proof were needed,
the importance of the concentrations achieved compared to the
doses administered, a factor that not always guarantees the shift
of the results from preclinical studies to man. In this regard, the
case of the CUR is exemplary. Due to its low lipophilicity and low
bioavailability (for an extensive review on the pharmacokinetics
of CUR, see Calabrese et al., 2008), CUR must be administered
in high doses to a maximum of 8 g/day. Clinical studies have
shown that the administration of CUR at doses of 1–4 g/day PO
for 6 months is able to determine plasma concentrations of 250–
270 nM within 4 h from administration which are reduced to
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60 nM after 24 h (Baum et al., 2008). When administered for
a shorter time, as in the study by Garcea et al. (2004) in which
CUR was administered at doses of 450–3600 mg/day PO for
1 week in subjects with colorectal cancer, the plasma concentra-
tion decreased to 3 nM. Regarding a supramaximal dose of CUR
(10–12 g single dose orally to healthy volunteers), the plasma con-
centration achieved was around 160 nM (Lao et al., 2006). As
regards tissue concentrations, the data available are rather lim-
ited. In patients with colorectal cancer and treated with CUR
1.8 to 3.6 g/day for 7 days, concentrations in colorectal tumor
tissue and normal tissue were, respectively ∼7 and 20 nmol/g
(Garcea et al., 2005). Based on these concentrations, it is diﬃcult
to imagine the eﬀects in humans of CUR that, in several preclin-
ical models, has proven eﬀective in the range 5–50 μM (Garcea
et al., 2005; Calabrese et al., 2008; Mancuso et al., 2012a), i.e.,
concentrations approximately 25–250 times higher than those
in plasma; the calculation compared to the concentrations of
CUR in the tissues is more diﬃcult, and may appear less accu-
rate, although the order of magnitude may be the same or even
greater.
Metabolism and Elimination
The possibility that dietary supplements interact with drug
metabolizing enzymes is no longer a matter of debate. Among
these enzymes there are isoforms of cytochrome P450 (CYP)
and UDP-glucuronosyltransferases (UGT) and sulfotransferases
(SULT). The several isoforms of CYP account for phase I
metabolism, whereas both UGT and SULT are responsible for
phase II reactions. In most cases, both phase I and phase II
enzymes increase the hydrophilicity of drugs promoting their
elimination, while only a small number of drugs, so-called pro-
drugs, needs activation, usually mediated by CYP, to give rise
to a pharmacological action (Rautio et al., 2008). The exten-
sive discussion of interactions among herbal products with drug
metabolizing enzymes is out of the scope of this article, interested
readers can refer to many comprehensive reviews in the literature
on this topic (Na et al., 2011; Gurley et al., 2012; Hermann and
von Richter, 2012).
Numerous studies have been conducted to evaluate the eﬀects
of dietary supplements on drug metabolizing enzymes, although
not always the results were consistent. There are several reasons
that do not always ensure univocity of evidence, including the
diﬀerent experimental systems used (e.g., the use of cell lines vs.
laboratory animals vs. clinical studies), the doses administered
and the resulting blood/tissue concentrations reached, above
all, the use of individual components of the multicomponent
herbal products versus extracts. A typical example is the EGCG
that in studies of human hepatocytes or immortalized cell lines
induced the CYP1A1 isoform, while in S. typhimurium muta-
genesis assay it noncompetitively inhibited CYP1A1, CYP2C9,
and CYP3A4 (Williams et al., 2000; Allen et al., 2001; Muto
et al., 2001; Shord et al., 2009). Green tea extracts also inhib-
ited the activity of SULT 1A1 and SULT1A3 in a recombinant
model of human SULT (Nishimuta et al., 2007; Nagai et al., 2009).
Studies on rodents supplemented with various types of green tea
showed a moderate induction of CYP1A and UGT in the liver
(Maliakal and Wanwimolruk, 2001; Niwattisaiwong et al., 2004;
Jang et al., 2005). Lastly, 42 healthy volunteers supplemented
with 200 mg EGCG orally for 4 weeks showed a small yet sig-
niﬁcant reduction in CYP3A4 activity (Chow et al., 2006). These
results were not conﬁrmed in another study in which 11 healthy
volunteers were treated for 14 days with two capsules/day of
green tea containing 200 mg of EGCG, but in the absence of
caﬀeine. This last datum further conﬁrms the confounding role
of any additional components in of the raw extracts of herbal
products and not directly related to the puriﬁed active princi-
ple(s) (Donovan et al., 2004). The possible confounding role of
additional components in the preparations obtained from the
herbal raw material could also aﬀect the results of clinical tri-
als designed to evaluate the eﬀectiveness of herbal products. The
intake of puriﬁed active principles allow, for instance, an accu-
rate titration of the administered dose versus the therapeutic
eﬀects and would be of great help in the identiﬁcation of speciﬁc
clinical outcomes, thus making the design of clinical trials more
eﬀective.
Pharmacodynamic Factors
In recent years, numerous studies have shown dietary supple-
ments are able to regulate many intracellular pathways involved
in the mechanisms of cytoprotection/cytotoxicity. Several papers
are available in literature showing inhibitory interactions between
herbal products and clearly cytotoxic signaling systems [e.g., the
inducible isoforms of nitric oxide synthase (iNOS) or cyclooxy-
genase (COX-2), NADPH oxidase] and stimulatory interactions
on cytoprotective signaling systems [e.g., superoxide dismutases,
catalase, heme oxygenase-1 (HO-1), etc.]. However, one aspect
is not always rightly pointed out and on which more and more
attention should be focused in the future, is the assessment of
some of these cellular systems with borderline eﬀects, that are
cytoprotective or cytotoxic on the basis of the type of cell or
tissue and their redox state. For example, NADPH oxidase is
a membrane enzyme that, in the presence of NADPH, is able
to transfer electrons to molecular oxygen generating free radi-
cals, such as superoxide anion, which, in some compartments,
is further converted to hydrogen peroxide (for an extensive
review see Seifert and Schultz, 1991). Due to its ability to gen-
erate ROS, NADPH oxidase is considered to play a key role
in atherosclerosis, and inhibitors of these enzyme have been
shown to counteract plaque formation (Meyer and Schmitt, 2000;
Yokoyama et al., 2000). On the other hand, in phagosomes
NADPH oxidase-derived superoxide and secondary ROS play
an anti-infective role because they contribute to kill bacteria
and fungi (Segal, 2005). Therefore, dietary supplements, such as
QCT and CUR, which reduce NADPH oxidase activity in sev-
eral preclinical models of atherosclerosis are considered potential
adjuvant agents in the prevention or chronic treatment of car-
diovascular diseases (Deby-Dupont et al., 2005; Sánchez et al.,
2006; Romero et al., 2009). On the other hand, the NADPH
oxidase inhibition mediated by these natural compounds could
decrease ROS formation in fagosomes, thus reducing micro-
bial killing and transforming these compounds in pro-infective
agents (Figure 4). Similarly, the induction of HO-1 is considered
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FIGURE 4 | Chronic supplementation with quercetin (QCT) and
curcumin (CUR): dual pharmacodynamic effects due to the interaction
with NADPH oxidase (NOX) and heme oxygenase-1 (HO-1). For further
information see text. BR, bilirubin; BV, biliverdin; CO, carbon monoxide; ROS,
reactive oxygen species; Fe+2, ferrous iron; H2O2, hydrogen peroxide; O·_2 ;
superoxide anion, –I, inhibition.
an early protective event in the cell stress response because it
degrades heme into carbonmonoxide, ferrous iron and biliverdin
which is further transformed, through the biliverdin reduc-
tase activity, into the powerful free radical scavenger biliru-
bin (Maines, 1997; Barone et al., 2009; Mancuso and Barone,
2009a; Mancuso et al., 2012b). However, a sustained induction
of HO-1, which could occur in the event of prolonged supple-
mentation with CUR, QCT, and other herbal products, could
be harmful because it (i) depletes cells of heme, which is nec-
essary as co-factor of several proteins, (ii) further increases the
release of both bilirubin and carbon monoxide, which become
per se toxic if produced in excess, and ferrous iron which trig-
gers Fenton reaction (Winterbourn, 1995) and generates ROS,
this latter being responsible for both lipid and protein oxida-
tion and cell death (Figure 4; Tang et al., 2013; Murphy et al.,
2014).
Safety Issues
On the basis of the above views, the induction or inhibition of
drug metabolizing enzymes by herbal products and the relative
changes of hemoconcentrations of any co-administered drugs,
are important factors that contribute to the onset of side eﬀects.
As previously explained, the literature data related to changes
of the enzyme activity of CYP, UGT, or SULT isoforms, are not
always univocal, indeed, they are sometimes also contradictory
and this has so far not allowed to state any deﬁnite theories
about the necessity or convenience, to avoid associations between
herbal products and certain medications. The main problems in
this regard have arisen since the majority of the evidence to sup-
port derived from preclinical studies carried out on cell lines or
laboratory animals without evidence of a direct eﬀect on humans.
For example, Golden et al. (2009) have shown that ECGC reduces
the cytotoxic activity of bortezomib, a boronic acid derivative
used to treat multiple myeloma or other malignancies, in mul-
tiple myeloma and glioblastoma cell lines. According to these
results, some articles in the literature recommend avoiding the
use of green tea in subjects treated with bortezomib (Mancuso
and Barone, 2009b; Shah et al., 2009; Jia and Liu, 2013). Studies
on rodents have shown that EGCG-related inhibition of CYP3A4
may increase blood concentrations of verapamil, diltiazem, or
midazolam determining potential toxic eﬀects (Muto et al., 2001;
Li and Choi, 2008; Chung et al., 2009). In the same experi-
mental model, the moderate induction of CYP1A by green tea
determined a reduced eﬀect for the antipsychotic drug clozap-
ine (Jang et al., 2005). However, direct evidence was obtained
from humans for a number of herbal products, thus provid-
ing unequivocal demonstrations of toxic interactions with drugs.
Ginkgo biloba is a herbal product with an excellent bioavailability
after oral administration (Kleijnen and Knipschild, 1992), ini-
tially considered useful as adjuvant treatment in dementia and
consequently dropped due to lack of clinical conﬁrmations (for
a recent review see Mancuso et al., 2012a). Chronic adminis-
tration of ginkgo biloba, which induces CYP2C19, signiﬁcantly
reduced the blood amounts, and therefore the clinical eﬃcacy,
of omeprazole particularly in individuals considered poor metab-
olizers (Yin et al., 2004). Moreover, because of the activation of
CYP2C19, ginkgo biloba has reduced the blood concentrations
of valproic acid and phenytoin in an epileptic subject causing
fatal seizures (Kupiec and Raj, 2005). Lastly, ginkgo biloba has
caused the state of coma in an 80-year-old individual suﬀering
from Alzheimer’s disease and treated with trazodone (Galluzzi
et al., 2000). This last adverse eﬀect was shown to be related to
the ginkgo biloba-mediated stimulation of CYP3A4 activity with
marked transformation of trazodone into the active metabolite
1- (m-chlorophenyl) piperazine which increased the GABAergic
tone in the brain and precipitated coma (Galluzzi et al., 2000).
Another exception must be made for the grapefruit juice for
which there is clinical evidence of dangerous drug interactions.
Indeed, grapefruit is rich in furanocoumarins, also well absorbed
following grapefruit intake (Uesawa et al., 2008; Messer et al.,
2011) which are responsible for the inhibition of CYP3A4 iso-
form responsible for the metabolism of many drugs. The intake
through a diet grapefruit has increased the blood concentrations
of ethinylestradiol and caused deep venous thrombosis from the
external iliac vein distal to the calf veins (Grande et al., 2009) in
a 42-year-old woman. The intake of grapefruit juice is not rec-
ommended in patients treated with simvastatin and lovastatin
because of a high risk of toxic eﬀects, such as rhabdomyolysis
(Dreier and Endres, 2004; Neuvonen et al., 2008). The dietary
intake of grapefruit juice increased the hemoconcentrations of
nifedipine and caused signiﬁcant hypotensive eﬀects in a 50-
year-old man with essential hypertension (Nakagawa and Goto,
2010).
Conclusion
The above considerations highlight the diﬃculties faced by
researchers when deciding on the possibility or not to
start studying the herbal-derived products as adjuvants to
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conventional therapies for many diseases in which free radicals
play a prevalent pathogenic role. Some problems, such as those
related to the absorption and distribution of herbal products can
be overcome with the help of medicinal chemistry that allows to
enhance better absorbed formulations when administered orally,
and to reach high concentrations of active ingredient in target
organs and tissues. Unfortunately, to date there are no suﬃcient
clinical studies demonstrating the eﬃcacy and safety of these
new formulations; in this respect, greater interaction is advocated
among researchers who are committed to the preparation and
preclinical evaluation of these formulations, often belonging to
non-proﬁt institutions, with the pharmaceutical industry, which
would have the ﬁnancial resources to design and implement
clinical trials.
The problems stemming from the modulation by herbal prod-
ucts of drug metabolizing enzymes are diﬃcult to manage. What
makes it even more diﬃcult is to avoid side-eﬀects arising
from the simultaneous intake of medications, dietary or as a
supplement, with herbal products and the almost total lack of
risk perception by patients. Who would ever think that eating a
grapefruit for breakfast or drinking 2–3 glasses of grapefruit juice
a day (in particular in warm periods of the year) can pose a seri-
ous health risk in case of simultaneous intake of progestogens,
statins, or nifedipine? An evenmore unacceptable risk when con-
sidering that the most aﬀected could be vulnerable populations,
such as, possibly, the elderly aﬀected by heart disease. A serious
approach to solving this problem would provide accurate infor-
mation on potential risks arising from a prolonged use of herbal
products, always recommending medical supervision and shelv-
ing the idea that everything is “natural” is “healthy” and “devoid
of risks.”
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